Research Line 2: According to the WHO, psychiatric diseases, such as depression, attention disorders and addiction will be the leading cause of disability worldwide by 2020 with costs exceeding $43 billion/year in the US alone.
In the Priority Medicine Program the large gap between treatment needs and availability is especially underscored for psychiatric disorders. Animal models for psychiatric disorders often poorly represent the human psychiatric disease state restricting novel target finding and testing of lead compounds for these diseases. Together with heterogeneous patient cohorts during clinical development, this creates an extremely high attrition of drug candidates.
Therefore, well before the testing of drug efficacy in the clinical phase, there is a great need to apply early lead compound assessment technologies.